Some raw digs into Charles Lieber, Nanosys, Vista Therapeutics, InQTel etc

NANOSYS INC / IN-Q-TEL (CIA)

October 20, 2003

Palo Alto, CA

Nanosys Inc., a leader in nanotechnology-enabled systems, announced today that it has signed a multi-million dollar strategic development deal with In-Q-Tel, a private nonprofit group funded by the Central Intelligence Agency.

Nanosys’ novel and patent-protected nanotechnology-enabled systems are based on inorganic semiconductor nanostructures. These nanostructures integrate functional complexity directly into each individual nanoparticle, enabling the low-cost fabrication of revolutionary high-value, high-performance applications.

“Nanosys’ technology has the potential to radically enhance the flexibility, size and power of applications across a wide range of industries,” said Gilman Louie, CEO of In-Q-Tel. “In-Q-Tel continues to seek innovative technologies that address some of the most difficult challenges in commercial enterprises and the national security community. Nanosys’ proprietary technology offers great promise for leading edge applications for customers in both of these markets.

https://www.iqt.org/nanosys-signs-deal-with-in-q-tel-to-support-development-of-nanotechnology-enabled-systems/

*small thread with more Nanosys info - https://threadreaderapp.com/thread/1242261275578642437.html

NANOSYS Inc / VISTA THERAPEUTICS / HARVARD

Cambridge , MA , Palo Alto , CA , Santa Fe , NM and Louisville , KY , (February 20, 2009) — Harvard University ‘s Office of Technology Development (OTD), Nanosys Inc., and Vista Therapeutics, Inc. today announced that Vista has signed License Agreements with both Harvard University and Nanosys covering several patents and patent applications related to the use of nanowires for biosensors. The core intellectual property (IP) involves a wide range of applications in nanotechnology, nanomaterials and the use of nanowire-based field effect transistors (FETs) as biosensors, all of which were derived from the work of Dr. Charles Lieber, a professor of Chemistry at Harvard, and a pioneer in nanotechnology.

Under terms of the agreements, Vista has secured the exclusive, worldwide rights for the use of nanowires for detection of biomarkers associated with organ or tissue damage, and any form of treatment or therapeutics-associated adverse response(s). In consideration, Harvard and Nanosys have received an equity position in Vista, as well as upfront license and downstream royalty payments.

While Harvard and Nanosys each own extensive portfolios of IP around multiple aspects of nanotechnology including basic nanowire compositions, nanowire synthesis and the use of nanowires and other nanostructures for many applications, Vista will focus its attention on the use of nanowire-based FETs as highly sensitive sensors of biomolecules. The power of Lieber’s nanotechnology inventions is that they permit continuous and real-time monitoring of multiple biomarkers in blood and urine. Vista plans to manufacture and sell nanowires that are formatted to provide real-time, continuous measurement of blood and urinary biomarkers of organ and tissue injury.

https://www.nanosysinc.com/news/2009/02/20/harvard-university-and-nanosys-license-nanowire-biosensor-systems-to-vista-therapeuticsSOME

CONT.

>>8780589

Cont.

DR. CHARLES LIEBER / CHINA / WUHAN UNIVERSITY OF TECH / DOJ CASE

Harvard University Professor and Two Chinese Nationals Charged in Three Separate China Related Cases

The Department of Justice announced today that the Chair of Harvard University’s Chemistry and Chemical Biology Department and two Chinese nationals have been charged in connection with aiding the People’s Republic of China.

Dr. Charles Lieber, 60, Chair of the Department of Chemistry and Chemical Biology at Harvard University, was arrested this morning and charged by criminal complaint with one count of making a materially false, fictitious and fraudulent statement. Lieber will appear this afternoon before Magistrate Judge Marianne B. Bowler in federal court in Boston, Massachusetts.

https://www.justice.gov/opa/pr/harvard-university-professor-and-two-chinese-nationals-charged-three-separate-china-related

VISTA THERAPEUTICS (founders- CHARLES LIEBER and SPENCER FARR)

(FROM WEBSITE)

Vista is seeking partners

Possible areas for collaboration

Areas for co-development and partnership:

Rapid field diagnostic for Zika, Ebola, dengue and other viral infections

Rapid field diagnostic for malaria

Co-use of NanoBioSensor to select best mABs, aptamers, etc.

Develop prep kits for urine, tears, CSF and tissues

Co-develop NanoBioSensor for continuous animal/patient monitoring

Co-develop bedside and field (hand-held) versions

Co-develop smart-phone and/or wireless versions

Use of NanoBioSensor for pharmacokinetics and toxicokinetics

Evaluate transcripts and proteins from same tissue samples

Air and water quality sampling/monitoring

Kidney dialysis monitoring

Surgical monitoring

Post-op sepsis monitoring

https://www.vistatherapeutics.org/Business-Seeking.html

CONT.

>>8780608

LIEBER RESEARCH GROUP SPONSORS

Office of Naval Research

Defense Advanced Research Projects Agency

Air Force Office of Scientific Research

National Institutes of Health

MITRE

http://cml.harvard.edu/resources/research-sponsors

SPENCER FARR

Spencer Farr, Ph.D. studied engineering and genetics at UC. Berkeley. He earned a Ph.D. in Molecular and Cell Biology at the University of New Mexico School of Medicine and the Institut Jacques Monod in Paris France, where he was a Fulbright Scholar. Spencer was an NIH post-doctoral fellow in Bruce Ames lab at UC. Berkeley and then joined the faculties of Harvard and MIT in molecular toxicology. He was the founder and CEO of Xenometrix Inc., Phase-1 Molecular Toxicology Inc., and Vista Therapeutics, Inc. Vista Therapeutics applies proprietary nanotechnology to the field of clinical medicine and drug development.

Specialties: Spencer has deep knowlege in the fields of toxicology, drug safety assessment and nanotechnology applied to biomedicine. He has extensive experience in starting, capitalizing and managing very high-technology companies.

https://www.linkedin.com/in/spencer-farr-ph-d-15ab764

DR. SPENCER B. FARR is the CEO and Founder of PHASE-1 Molecular

Toxicology, Inc. He was a member of the scientific advisory board to the

U.S. Food and Drug Administration during 1998 and 1999. Dr. Farr

currently serves on the editorial board of In Vitro Toxicology, Genetic

Engineering News, and Toxicological Sciences and the grant review

committees of the American Cancer Society, National Institutes of Health

and National Science Foundation. He was an Assistant Professor in the

Department of Cellular and Molecular Toxicology at the Harvard School of

Public Health and a member of the Center for Environmental Health

Sciences at the Massachusetts Institute of Technology. Dr. Farr received his Bachelor of Science degree in Genetics from the University of California at Berkeley and his PhD from the University of New Mexico

School of Medicine and the Institut Jacques Monod, Paris, France.

https://www.twst.com/bio/dr-spencer-b-farr/

SPENCER FARR / XENOMETRIX INC

D. H. Blair Investment Banking in New York backed the technology, permitting Farr to establish his first startup, Xenometrix Inc.

In 1990, Farr established the company in Boulder, Colo., so he could return to the West.

“I liked being a teacher, but I’m a Westerner down to my stem cells,” Farr said.

The company raised a total of $20 million in venture capital and went public in 1994. A group of Swiss investors later purchased the firm.

Farr and his wife then moved to Santa Fe, where he created his second startup, Phase-I Molecular Technology Inc. That company used personal genomics to assess an individual’s response to drugs.

It was a major success. It raised $15 million in venture capital, and in 2000, it pre-sold $350 million in shares in preparation to go public, Farr said. But two days before the IPO, the U.S. and British governments decided to block private ownership of genomic codes, derailing the IPO.

Private offers followed, but after investors turned them down, Farr left the company. Phase-I declared bankruptcy in 2002.

Farr worked as executive vice president of drug development for Potentia Pharmaceuticals Inc. for three years. Then, in 2006, he licensed new technology from Harvard to launch Vista Therapeutics.

The company is developing a nanotechnology-based device to continuously monitor body fluids in trauma patients. The technology could significantly improve treatment, because today, doctors must send blood, urine or other samples to labs for analysis.

The startup has raised nearly $2 million in venture capital, including money from the New Mexico Angels.

“It’s game-changing technology,” said Angels President John Chavez. “The market is enormous. That’s why we invested in it.”

ICx Technologies Inc. in Albuquerque has developed software and hardware for the new device, called a NanoBioSensor. In addition, ICx Vice President Chuck Call took a small equity stake in Vista Therapeutics.

“He’s truly a gifted individual,” Call said of Farr. “He’s an extremely creative serial entrepreneur.”

Both Call and Chavez are partners in Phase One Ventures, which is seeking to commercialize new technologies from UNM and the labs. Although the founding partners jointly created Phase One, the initial idea came from Farr.

“It was my dumb idea,” Farr said. “If we’re successful, then it’s our joint brilliant idea.”

The Farrs have two daughters, Michaela, 19, and Sophie, 12. Apart from their home in Santa Fe, they have a working ranch, with cows and horses, near Chama, in northern New Mexico.

https://www.bizjournals.com/albuquerque/stories/2010/05/17/story8.html

CONT.

>>8780635

XENOMETRIX

Note from above that Swiss investors purchased Xenometrix in 1994.

I believe this site is what became of Xenometrix Inc

https://www.xenometrix.ch

Note the tagline "Swiss commitment for Bioassays"

Also of note is the .ch domain. .ch=China

Other articles related to Xenometeix - https://bciq.biocentury.com/companies/xenometrix_inc

XENOMETRIX PURCHASED BY DISCOVERY PARTNERS

Discovery Partners International Inc. (San Diego) announced today that it has entered into a definitive agreement to acquire Xenometrix, Inc., a company that has proprietary gene profiling technology. Xenometrix's technology provides important efficacy and safety data with regard to a compound's potential therapeutic and toxic effects, allowing scientists to streamline the drug development process, according to Riccardo Pigliucci, Chief Executive Officer of Discovery Partners.

Under the terms of the agreement, Discovery Partners will acquire all of Xenometrix's common stock for $0.59 cash per Xenometrix share. Xenometrix will become a wholly owned subsidiary of Discovery Partners. The transaction, which has been approved by the Boards of Directors of both companies, is subject to approval by Xenometrix stockholders and customary closing conditions and is expected to close in the second quarter of this year.

Xenometrix holds a strong patent portfolio for its gene profiling technology, which Discovery Partners will be able to leverage. In particular, Xenometrix shares ownership of some patents with Harvard University and has an exclusive worldwide license to Harvard's ownership interests in the intellectual property. Xenometrix has granted non-exclusive licenses to over twenty companies who are leaders in different aspects of genomics including: Affymetrix, Aurora Biosciences, Corning, Gene Logic, GeneTrace, Genometrix, Genzyme, Motorola, Packard, Pfizer, Phase-1, Rosetta Inpharmatics and SmithKline Beecham. In addition to gene profiling technology, Discovery Partners gains exclusive licenses to the technology that enables high throughput screening for genotoxicity from GeneBioMed, Inc. and the University of California, Berkeley.

https://www.drugdiscoveryonline.com/doc/discovery-partners-international-to-acquire-x-0002

XANTHON INC SUBSIDIARY OF XENOMETRIX INC

DESCRIPTION OF DOD CONTRACT

An electrochemical DNA biosensor is proposed to simultaneously detect and identify multiple nucleic acid determinants of a variety of pathogens using a combination of electronic hybridization, fluidics, and electrochemical detection. The biosensor wouldconsist of a sample lysis and electronic hybridization/release chamber fluidically connected to an electrochemical flow cell for detection, and would incorporate Xanthon's patented platform technology of electrochemical detection of nucleic acids. Withthis method, specific target nucleic acid species captured by oligo capture probes are directly detected by the electrochemical oxidation of guanine, an endogenous component of the nucleic acid targets. This provides a method of rapid, highly sensitive,and specific DNA detection without the need for complicated sample purification procedures, exogenous labels, labile reagents, or expensive, heavy, power-hungry instrumentation. Upon successful demonstration of the feasibility of the basic components,plans for further miniaturization and integration of the components will proceed toward development of a rugged, easy-to-use handheld unit that will take further advantage of the power and simplicity of direct electrochemical detection, in addition to theeconomy of time, space, and reagents made possible by microfluidics and electronic hybridization. In addition to military applications, development of such devices would provide prompt detection of potential bio-terrorist attacks, and find wide applicationfor the detection of pathogens in medical diagnostics, point-of-care clinical settings, food production, environmental monitoring, agriculture, and various industrial settings.

https://www.sbir.gov/node/352082

CONT

>>8780666

DISCOVERY PARTNERS - history with Soros connect

Pigliucci received a degree in industrial chemistry from the Chemical Institute of Milan, Italy, in 1966 and subsequently went to work as a chemist for Perkin-Elmer Corporation, a worldwide life science and analytical instrument company based in Norwalk, Connecticut. Over the next 30 years he held a variety of positions in both Europe and the United States, working in product development, sales, and marketing. He became corporate vice president in 1989 and president and chief operating officer in 1993, the same year that he was a leading strategist on a major acquisition of Applied Biosystems Inc. Piglucci appeared to be the heir apparent to CEO Gaynor N. Kelley as he approached the mandatory retirement age of 65, but in March 1995, a year early, Kelley announced that the company would conduct an outside search for his successor and that Pigliucci was just another candidate. As reported by the Wall Street Journal at the time, "A couple of big shareholders, including the George Soros fund and money manager Neuberger & Berman, have been rattling management's cage, pushing for better stock performance." Within two months Pigliucci resigned, admitting that the outside search was a contributing factor: "It made it a difficult working environment; it's better to leave while you're ahead. … I think it was easier for everyone that I disappear into the background." Several months later Pigliucci resurfaced as the CEO of Life Sciences International PLC, a position he held until his involvement with IRORI.

https://www.company-histories.com/Discovery-Partners-International-Inc-Company-History.html

Stumbled upon these articles digging down the same hole (haven't vetted)

https://aim4truth.org/2020/03/28/charles-m-lieber-and-the-queens-qinetiq/

https://aim4truth.org/2020/03/12/cat-report-331/